Literature DB >> 27770171

Should we take into account ESBLs in empirical antibiotic treatment?

Matteo Bassetti1,2, Jesús Rodríguez-Baño3.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27770171     DOI： 10.1007/s00134-016-4599-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  15 in total

Review 1.  Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae.

Authors:  Muriel Gazin; Fabienne Paasch; Herman Goossens; Surbhi Malhotra-Kumar
Journal:  J Clin Microbiol       Date:  2012-01-18       Impact factor: 5.948

Review 2.  The new beta-lactamases.

Authors:  George A Jacoby; Luisa Silvia Munoz-Price
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

3.  Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.

Authors:  Mario Tumbarello; Teresa Spanu; Maurizio Sanguinetti; Rita Citton; Eva Montuori; Fiammetta Leone; Giovanni Fadda; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism.

Authors:  Katherine E Goodman; Justin Lessler; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Jennifer H Han; Aaron M Milstone; Colin J Massey; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2016-06-28       Impact factor: 9.079

5.  Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology.

Authors:  Jesús Rodríguez-Baño; José Miguel Cisneros; Nazaret Cobos-Trigueros; Gema Fresco; Carolina Navarro-San Francisco; Carlota Gudiol; Juan Pablo Horcajada; Lorena López-Cerero; José Antonio Martínez; José Molina; Milagro Montero; José R Paño-Pardo; Alvaro Pascual; Carmen Peña; Vicente Pintado; Pilar Retamar; María Tomás; Marcio Borges-Sa; José Garnacho-Montero; Germán Bou
Journal:  Enferm Infecc Microbiol Clin       Date:  2015-01-15       Impact factor: 1.731

6.  Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?

Authors:  François Barbier; Cécile Pommier; Wafa Essaied; Maïté Garrouste-Orgeas; Carole Schwebel; Stéphane Ruckly; Anne-Sylvie Dumenil; Virginie Lemiale; Bruno Mourvillier; Christophe Clec'h; Michaël Darmon; Virginie Laurent; Guillaume Marcotte; Jean-Christophe Lucet; Bertrand Souweine; Jean-Ralph Zahar; Jean-François Timsit
Journal:  J Antimicrob Chemother       Date:  2016-01-10       Impact factor: 5.790

7.  Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.

Authors:  Olaf Burkhardt; Vipul Kumar; Denise Katterwe; Jolanta Majcher-Peszynska; Bernd Drewelow; Hartmut Derendorf; Tobias Welte
Journal:  J Antimicrob Chemother       Date:  2006-12-21       Impact factor: 5.790

8.  Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2013-12-06       Impact factor: 2.803

9.  Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission.

Authors:  Anthony D Harris; Jessina C McGregor; Judith A Johnson; Sandra M Strauss; Anita C Moore; Harold C Standiford; Joan N Hebden; J Glenn Morris
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

10.  A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.

Authors:  Ian Morrissey; Meredith Hackel; Robert Badal; Sam Bouchillon; Stephen Hawser; Douglas Biedenbach
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-01
View more
  2 in total

Review 1.  Focus on severe infections.

Authors:  Kevin B Laupland; Jose-Artur Paiva; Jean-Francois Timsit
Journal:  Intensive Care Med       Date:  2017-05-13       Impact factor: 17.440

2.  Factors associated with bacteraemia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study.

Authors:  Hélène Mascitti; Clara Duran; Elisabeth-Marie Nemo; Frédérique Bouchand; Ruxandra Câlin; Alexis Descatha; Jean-Louis Gaillard; Christine Lawrence; Benjamin Davido; François Barbier; Aurélien Dinh
Journal:  Antimicrob Resist Infect Control       Date:  2018-09-29       Impact factor: 4.887
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.